Arizona State Retirement System Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Arizona State Retirement System lowered its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,164 shares of the biotechnology company’s stock after selling 380 shares during the period. Arizona State Retirement System’s holdings in Sarepta Therapeutics were worth $2,137,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of SRPT. Montag A & Associates Inc. purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth approximately $30,000. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares in the last quarter. KB Financial Partners LLC purchased a new stake in shares of Sarepta Therapeutics during the first quarter worth $36,000. Qube Research & Technologies Ltd acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $33,000. Finally, Ossiam purchased a new position in shares of Sarepta Therapeutics in the first quarter worth about $105,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Ian Michael Estepan sold 1,200 shares of Sarepta Therapeutics stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the transaction, the director now owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock worth $2,739,419 over the last 90 days. 7.40% of the stock is owned by insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $124.45 on Friday. The company has a market cap of $11.69 billion, a P/E ratio of -20.33 and a beta of 0.94. The firm has a fifty day moving average price of $127.42 and a 200 day moving average price of $110.50. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The company had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. During the same period in the previous year, the business earned ($1.24) EPS. Sarepta Therapeutics’s revenue for the quarter was up 53.6% on a year-over-year basis. Sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. TheStreet upgraded shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Mizuho increased their price target on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. UBS Group boosted their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Wedbush reaffirmed an “outperform” rating and issued a $224.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Finally, Royal Bank of Canada lifted their price target on Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.38.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.